Author:
Ansari L,Shiehzadeh F,Taherzadeh Z,Nikoofal-Sahlabadi S,Momtazi-borojeni A A,Sahebkar A,Eslami S
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference18 articles.
1. Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G et al. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 2004; 27: 441–446.
2. Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I–II clinical investigation. Oncology 2002; 63: 23–30.
3. Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32: 18–24.
4. Alexopoulos A, Karamouzis MV, Stavrinides H, Ardavanis A, Kandilis K, Stavrakakis J et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15: 891–895.
5. Verma S, Dent S, Chow BJ, Rayson D, Safra T . Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008; 34: 391–406.
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献